(Q42807626)

7 November 2017

title

Safety of anacetrapib in patients with or at high risk for coronary heart disease (English)

1 reference

7 November 2017

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease (English)

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

28 August 2024

0 references

1

Christopher P Cannon

1 reference

7 November 2017

5

Eliot A Brinton

1 reference

7 November 2017

Sukrut Shah

2

1 reference

7 November 2017

Michael Davidson

4

1 reference

7 November 2017

Michael Stepanavage

7

1 reference

7 November 2017

Sherry Xueyu Liu

8

1 reference

7 November 2017

Patrice Gibbons

9

1 reference

7 November 2017

Jennifer Zafarino

11

1 reference

7 November 2017

Yale Mitchel

12

1 reference

7 November 2017

Philip Barter

13

1 reference

7 November 2017

Determining the Efficacy and Tolerability Investigators

14

1 reference

7 November 2017

Hayes M. Dansky

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21082868

28 August 2024

Antonio M. Gotto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21082868

28 August 2024

Tanya B. Ashraf

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21082868

28 August 2024

language of work or name

English

0 references

publication date

17 November 2010

1 reference

full work available at URL

7 November 2017

https://doi.org/10.1056/nejmoa1009744

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21082868

http://content.nejm.org/cgi/content/abstract/363/25/2406

28 August 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21082868

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009744

28 August 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

The New England Journal of Medicine

28 August 2024

published in

1 reference

7 November 2017

volume

363

1 reference

7 November 2017

issue

25

1 reference

7 November 2017

page(s)

2406-2415

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

7 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

28 August 2024

2

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

28 August 2024

3

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

28 August 2024

4

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

28 August 2024

5

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Effects of torcetrapib in patients at high risk for coronary events

28 August 2024

6

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients

28 August 2024

7

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

28 August 2024

8

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

28 August 2024

9

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

28 August 2024

10

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

28 August 2024

12

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

28 August 2024

13

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

28 August 2024

14

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

28 August 2024

15

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

28 August 2024

16

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1009744

28 August 2024

Identifiers

1 reference

7 November 2017

1 reference